

Table S1. Companion tuberculosis drugs administered to patients with multidrug-resistant tuberculosis treated with delamanid and/or bedaquiline

	Total (n=61)	Delamanid alone (n=11)	Bedaquiline alone (n=39)	Both drugs (n=11)	p value
Rifabutin	4 (6.6)	1 (9.1)	2 (5.1)	1 (9.1)	0.615
Ethambutol	9 (14.8)	0 (0)	8 (20.5)	1 (9.1)	0.260
Pyrazinamide	26 (42.6)	5 (45.5)	18 (46.2)	3 (27.3)	0.568
Streptomycin	11 (18.0)	1 (9.1)	9 (23.1)	1 (9.1)	0.435
Kanamycin	17 (28.3)	1 (9.1)	12 (31.6)	4 (36.4)	0.328
Amikacin	13 (21.3)	4 (36.4)	6 (15.4)	3 (27.3)	0.250
Capreomycin (or viomycin)					
Cycloserine	48 (78.7)	9 (81.8)	33 (84.6)	6 (54.5)	0.136
Prothionamide	46 (75.4)	9 (81.8)	31 (79.5)	6 (54.5)	0.236
Para-aminosalicylic acid	27 (44.3)	5 (45.5)	19 (48.7)	3 (27.3)	0.529
Ofloxacin	0	0	0	0	0
Levofloxacin	15 (24.6)	3 (27.3)	10 (25.6)	2 (18.2)	1.000
Moxifloxacin	24 (39.3)	5 (45.5)	18 (46.2)	1 (9.1)	0.087
Clarithromycin*	14	1 (9.1)	7 (17.9)	6 (54.5)	0.019

	(23.0)				
Amoxicillin-clavulanic acid	18 (29.5)	1 (9.1)‡	9 (23.1)+	8 (72.7)+‡	0.002
Meropenem	4 (6.6)	1 (9.1)	2 (5.1)	1 (9.1)	0.615
Clofazimine*	12 (19.7)	1 (9.1)	5 (12.8)	6 (54.5)	0.011

Results reported as n (%)

*+‡Dunn's post hoc test was performed when the result of the Kruskal-Wallis test was significant: * $p > 0.05$ among groups; +bedaquiline vs both drugs, $P < 0.05$; ‡delamanid vs both drugs, $P < 0.05$.

Table S2. Factors related to culture conversion

Patient characteristic	Culture conversion (n = 39)	Persistently positive (n = 16)	p value
Age ≥45 years	27 (69.2)	11 (68.8)	1.000
Sex, male	31 (79.5)	14 (87.5)	0.706
Body mass index <18.5 kg/m ²	13 (33.3)	6 (37.5)	0.765
Previous treatment history for tuberculosis	31 (79.5)	14 (87.5)	0.706
Previously treated for multi-drug resistant tuberculosis	22 (56.4)	11 (68.8)	0.547
Smear-positive sputum	24 (61.5)	8 (50.0)	0.550
Presence of a cavity (or cavities)	16 (41.0)	11 (68.8)	0.080
Bilateral disease	29 (74.4)	14 (81.3)	0.734
MDR-TB with SLID resistance	9 (23.1)	7 (43.8)	0.191
MDR-TB with FQ resistance	28 (71.8)	12 (75.0)	1.000
XDR-TB	9 (23.1)	5 (31.3)	0.519
Treatment with new drugs			

Delamanid	8 (20.5)	0 (0)	0.162
Bedaquiline	24 (61.5)	12 (75.0)	
Both delamanid and bedaquiline	7 (17.9)	4 (25.0)	
Treatment with linezolid	21 (53.8)	10 (62.5)	0.765
Treatment with fluoroquinolones	21(53.8)	11 (68.6)	0.377
Treatment with levofloxacin	8 (20.5)	5 (31.3)	0.489
Treatment with moxifloxacin	15 (38.5)	6 (37.5)	1.000
Duration of treatment with delamanid and/or bedaquiline, days	173.0 (167.0-190.0)	167.0 (129.5-226.0)	0.168*

Results reported as n (%) or median (interquartile range).

FQ, fluoroquinolone; MDR-TB, multidrug-resistant tuberculosis, SLID, second-line injectable drugs; XDR-TB, extensively drug-resistant tuberculosis